c5e09ad2-1f0b-4ea3-9565-a1664f1bb468
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ALLOGRAFT_REJECTION+0.500
- ANGIOGENESIS+0.500
- IL6_JAK_STAT3_SIGNALING+0.500
- INFLAMMATORY_RESPONSE+0.500
- COAGULATION+0.400
- COMPLEMENT+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- MYOGENESIS+0.400
- APICAL_JUNCTION+0.300
Top 10 suppressed
- MYC_TARGETS_V1-0.700
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V2-0.600
- OXIDATIVE_PHOSPHORYLATION-0.500
- PROTEIN_SECRETION-0.500
- DNA_REPAIR-0.400
- MITOTIC_SPINDLE-0.400
- MTORC1_SIGNALING-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclcA055A_S52.txt | — | cohortMD2 | 0.963 |
| 2 | sclc55A_S50.txt | — | cohortMD2 | 0.947 |
| 3 | SRR8613743 | — | D | 0.944 |
| 4 | GSM5359443 | — | — | 0.940 |
| 5 | SRR2689710 | — | — | 0.938 |
| 6 | TCGA-44-A47G-01A-21R-A24H-07 | — | cohortA1 | 0.937 |
| 7 | SJEPD001535_R2.RNA-Seq | EPN | Posterior Fossa EPN | 0.936 |
| 8 | SRR1489971 | GTEX | — | 0.935 |
| 9 | BS_B0SVFK4P | pleomorphic xanthoastrocytoma(PXA) | — | 0.933 |
| 10 | SRR2771286 | — | — | 0.932 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |